T. Rowe Price Associates
REPL icon

T. Rowe Price Associates’s Replimune Group REPL Stock Holding History

T. Rowe Price Associates’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.1M Sell
8,121,433
-140,863
-2% -$1.08M 0.01% 719
2025
Q4 		$80.3M Sell
8,262,296
-44,137
-0.5% -$375K 0.01% 681
2025
Q3 		$34.8M Sell
8,306,433
-2,512,776
-23% -$16.1M ﹤0.01% 902
2025
Q2 		$101M Sell
10,819,209
-34,623
-0.3% -$302K 0.01% 569
2025
Q1 		$106M Sell
10,853,832
-109,051
-1% -$1.35M 0.01% 541
2024
Q4 		$133M Buy
10,962,883
+1,083,633
+11% +$13.2M 0.02% 510
2024
Q3 		$108M Buy
9,879,250
+643,193
+7% +$6.53M 0.01% 552
2024
Q2 		$83.1M Buy
9,236,057
+2,687,127
+41% +$18.7M 0.01% 585
2024
Q1 		$53.5M Buy
6,548,930
+699,679
+12% +$5.74M 0.01% 713
2023
Q4 		$49.3M Buy
5,849,251
+56,052
+1% +$650K 0.01% 718
2023
Q3 		$99.1M Buy
5,793,199
+60,187
+1% +$1.18M 0.01% 516
2023
Q2 		$133M Buy
5,733,012
+237,396
+4% +$4.64M 0.02% 477
2023
Q1 		$97.1M Buy
5,495,616
+430,872
+9% +$10.2M 0.01% 516
2022
Q4 		$138M Buy
5,064,744
+893,573
+21% +$18.6M 0.02% 441
2022
Q3 		$72M Sell
4,171,171
-1,711,360
-29% -$32.6M 0.01% 553
2022
Q2 		$103M Sell
5,882,531
-140,229
-2% -$2.3M 0.01% 651
2022
Q1 		$102M Buy
6,022,760
+154,122
+3% +$2.91M 0.01% 728
2021
Q4 		$159M Buy
5,868,638
+151,598
+3% +$4.53M 0.01% 621
2021
Q3 		$169M Buy
5,717,040
+647,590
+13% +$21M 0.02% 600
2021
Q2 		$195M Buy
5,069,450
+1,991,208
+65% +$68.1M 0.02% 567
2021
Q1 		$93.9M Buy
3,078,242
+452,551
+17% +$16.9M 0.01% 799
2020
Q4 		$100M Buy
2,625,691
+2,199,530
+516% +$91.7M 0.01% 725
2020
Q3 		$9.81M Buy
426,161
+38,822
+10% +$885K ﹤0.01% 1304
2020
Q2 		$9.63M Buy
+387,339
New +$6.85M ﹤0.01% 1302
2019
Q2 		– Sell
-22,693
Closed -$345K – 2555
2019
Q1 		$345K Buy
+22,693
New +$283K ﹤0.01% 2251

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates's REPL Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Replimune Group (REPL) stake by 1.7% in Q1 2026, selling an estimated $1.08M and leaving 8,121,433 shares worth $62.1M. The position accounts for 0.01% of the portfolio, ranked #719.

T. Rowe Price Associates first reported a position in REPL in Q1 2019 and has held it in 25 quarters since. The position peaked at $195M in Q2 2021. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.

  • T. Rowe Price Associates held 8,121,433 shares of Replimune Group worth $62.1M as of Q1 2026.
  • T. Rowe Price Associates sold 140,863 Replimune Group shares in Q1 2026, an estimated $1.08M.
  • Replimune Group made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #719 holding.
  • T. Rowe Price Associates first reported a position in Replimune Group in Q1 2019 and has held it in 25 quarters since.
  • T. Rowe Price Associates's Replimune Group position peaked at $195M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.